Therapeutic Efficacy of Vitamin E δ-Tocotrienol in Collagen-Induced Rat Model of Arthritis

Nagaraja Haleagrahara, Mirashini Swaminathan, Srikumar Chakravarthi, and Ammu Radhakrishnan

1 Discipline of Physiology and Pharmacology, School of Veterinary and Biomedical Sciences, Faculty of Medicine, Health and Molecular Sciences, James Cook University, Townsville QLD 4811, Australia
2 Department of Pathology, Faculty of Medicine, International Medical University, 57000 Kuala Lumpur, Malaysia
3 Perdana University Graduate School of Medicine, 57000 Kuala Lumpur, Malaysia

Correspondence should be addressed to Nagaraja Haleagrahara; haleagrahara.nagaraja@jcu.edu.au

Received 14 February 2014; Revised 17 June 2014; Accepted 25 June 2014; Published 10 July 2014

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease primarily involving inflammation of the joints. Although the management of the disease has advanced significantly in the past three decades, there is still no cure for RA. The aim of this study was to determine the therapeutic efficacy of δ-tocotrienol, in the rat model of collagen-induced arthritis (CIA). Arthritis was induced by intradermal injection of collagen type II emulsified in complete Freund’s adjuvant. CIA rats were orally treated with δ-tocotrienol (10 mg/kg) or glucosamine hydrochloride (300 mg/kg) from day 25 to 50. Efficacy was assessed based on the ability to reduce paw edema, histopathological changes, suppression of collagen-specific T-cells, and a reduction in C-reactive protein (CRP) levels. It was established that δ-tocotrienol had the most significant impact in lowering paw edema when compared to glucosamine treatment. Paw edema changes correlated well with histopathological analysis where there was a significant reversal of changes in groups treated with δ-tocotrienol. The results suggest that δ-tocotrienol is efficient in amelioration of collagen-induced arthritis.

Vitamin E delta-tocotrienol may be of therapeutic value against rheumatoid arthritis.

1. Introduction

Rheumatoid arthritis is a chronic inflammatory and destructive arthropathy. The worldwide occurrence of RA is about 1–1.5% of the population and it does not discriminate between age and ethnicity [1]. The precise aetiology of RA remains unknown. It has been established however that this disease is strongly linked with major histocompatibility complex (MHC) class II antigens, suggesting a genetic predisposition [2]. The pathogenesis of RA is associated with the activation of both cellular and humoral immune responses to an autoantigen [2, 3]. The activation of such responses leads to a potentiation of various proinflammatory cytokines (TNF-α, IL-1β, etc.), cascading into a vicious cycle of antigenic stimulation, inflammation, and joint destruction [4]. Currently, only symptomatic treatment of RA is available. Treatment for RA is unsatisfactory, as it consists of drugs with serious side effects and does not correct the underlying causes of arthritis. Therefore, there is a dire need for a safer and equally, if not more, efficient treatment option which is able to attack the root of the disease itself.

Nutraceuticals are loosely defined as “functional foods” and food products that provide medicinal or health benefits [5]. With a reported market value of US$75 billion, this industry is becoming progressively popular, partly due to the public’s perception that “natural is better” [6]. Joining a long list of nutraceuticals are the tocotrienols, a constituent of vitamin E found in palm oil as a phytonutrient [7]. Vitamin E is a collective name for a complex mixture of homologues. The two main homologues of vitamin E are the tocopherols (T) and tocotrienols (T3). Each homology is subsequently composed of four isomers, α, β, γ, and δ. Tocomonoenol, found in small quantities in palm oil and marine organisms, forms the third homologue of vitamin E. Two isomers of
tocopherol have been described to date with not much known about either [8]. Gaining substantial momentum in
the past decade, tocotrienol research has led to the discovery
of many of its important properties. Ranging from anticancer
[9] to neuroprotective qualities [10], it is clear that tocotrienol
use in various disease states is warranted. One such disease
is rheumatoid arthritis (RA). The anti-inflammatory effects
of tocotrienols have been less studied. Only recently, it has
come to light that these isomers of vitamin E might bear some
consequences on eradicating chronic inflammatory diseases
such as arthritis, atherosclerosis, and coeliac disease to name
a few. The aim of the present study is to assess the efficacy of
\(\delta\)-tocotrienol supplementation as a therapeutic agent in
the collagen-induced rat model of arthritis.

2. Materials and Methods

Female Dark Agouti (DA) rats, 6–10 weeks old (150–200 g),
were obtained from the Institute of Medical Research (IMR),
Malaysia. Rats were maintained in individually ventilated
cages (4 per cage) in the Animal Holding Facility (AHF) at the
International Medical University (IMU) after their arrival.
Food and water were available to the animals ad libitum.
The AHF environment was climate-controlled with a 12-
hour day and 12-hour night cycles. The International Medical
University’s joint committee for research and ethics approved
all experimental procedures of this study. Delta-tocotrienol
was a kind gift from Davos Life Sciences (Singapore). Colla-
gen from chicken sternum cartilage type II, complete Freund's
adjuvant (CFA), glucosamine hydrochloride, and acetic acid
were obtained from the Institute of Medical Research (IMR),
and blood sample was collected by cardiac puncture. Joint
tissues were transferred to a tube containing

\[\text{2 mL of RPMI media and 3 mL of RBC lysis buffer were added to the}
\text{pelleted cells. The tube was inverted gently several times for}
\text{30 seconds to ensure mixture of the buffer and the pellet. Then,}
\text{the cells were centrifuged again at 800 rpm for 5 minutes and the}
\text{supernatant was discarded. The pellet was resuspended in 2 mL of}
\text{RPMI media and centrifuged again at 800 rpm for 5 minutes and the}
\text{supernatant was discarded. The pellet was then resuspended in 2 mL of RPMI media. For the counting}
\text{of cells, 100 \(\mu\)L of the cell suspension is diluted with 900 \(\mu\)L of}
\text{complete RPMI medium. Then, 20 \(\mu\)L of this suspension was}
\text{transferred into a microcentrifuge tube and 20 \(\mu\)L of}
\text{trypan-blue dye was added to the cells. The trypan-blue dye}
\text{dyes dead cells and this will help to eliminate the counting}
\text{of these cells. The suspension was transferred onto a glass}
\text{haemocytometer and viewed under the microscope. Viable}
\text{leukocytes were counted. The cell number was adjusted to}
\text{5 \(\times\) 10^6 cells/mL using the culture medium. About 200 \(\mu\)L of}
\text{this cell suspension was added in triplicate to the wells of a sterile}
\text{96-well flat-bottomed plate in the presence of}
\text{5 \(\mu\)g/mL collagen. The plate was left to incubate for 72 hours in a}
\text{humidified CO2 incubator at 37°C. Cell proliferation was}
\text{determined using the MTT assay.}

2.1. Collagen Stimulation of Splenic Leukocytes. For collagen
stimulation of splenic leukocytes, the tubes containing the
cell suspension were centrifuged at 800 rpm for 5 minutes
after which the supernatant was discarded. 1 mL of complete
RPMI medium and 3 mL of RBC lysis buffer were added to the
pelleted cells. The tube was inverted gently several times for
30 seconds to ensure mixture of the buffer and the pellet. Then, the cells were centrifuged again at 800 rpm for 5 minutes and the supernatant was discarded. The pellet was then resuspended in 2 mL of RPMI media. For the counting
of cells, 100 \(\mu\)L of the cell suspension is diluted with 900 \(\mu\)L of
complete RPMI medium. Then, 20 \(\mu\)L of this suspension was
transferred into a microcentrifuge tube and 20 \(\mu\)L of
trypan-blue dye was added to the cells. The trypan-blue dye
dyes dead cells and this will help to eliminate the counting
of these cells. The suspension was transferred onto a glass
haemocytometer and viewed under the microscope. Viable
leukocytes were counted. The cell number was adjusted to
5 \(\times\) 10^6 cells/mL using the culture medium. About 200 \(\mu\)L of
this cell suspension was added in triplicate to the wells of a sterile
96-well flat-bottomed plate in the presence of
5 \(\mu\)g/mL collagen. The plate was left to incubate for 72 hours in a
humidified CO2 incubator at 37°C. Cell proliferation was
determined using the MTT assay.

2.2. Histopathology. After being fixed in 10% formalin for one
week, the joint tissues were transferred to a tube containing
a decalciﬁying agent. Following decalcification, the tissue
was processed using an automated tissue processor and embed-
ding station. Blocks were sectioned at 3-4 \(\mu\)m thickness and
slides were prepared and stained (H&E).

2.3. Statistical Analysis. All data were analyzed using SPSS
version 18 (SPSS Inc., Chicago, IL, USA). One-way analysis
of variance (ANOVA) was used to detect differences among
the experimental groups. For detecting differences between
any two groups in a multiple group comparison, Tukey's test
was used to evaluate paw oedema data and readings obtained
from the ELISA. For all tests, a \(P\) value of less than 0.05 was
considered to be significant.

3. Results

3.1. The Severity of Arthritis. Arthritic animals began to have
restrictions in movement at around day 20 where signs of
arthritis began to develop. Some animals had developed a
limp and moved around dragging their paws. Eating patterns,
however, remained normal as denoted by a linear weight gain.
As treatment progressed from day 25 to day 50, the mobility of
Figure 1: Effect of delta-tocotrienol on hind-paw edema. Hind-paws on day 50 of the experiment. Normal rats (a) from control group showed no signs of joint inflammation. Gross morphology of the hind-paws of arthritis rats showed maximal swelling and redness over joints (b). Treatment with tocotrienol and glucosamine reduced the severity of paw inflammation ((c) and (d)).

3.2. Paw Edema. Paw edema was quantified by measuring paw size using a digital caliper from day 25 to 50. Arthritic animals began to show signs of arthritis between days 15 and 20. A total of 16 joints were measured for changes in swelling. Prior to induction, all rats showed no signs of arthritis or any paw deformities (Figure 1(a)). Signs of arthritis observed included swelling and redness over the joints, development of a limp, and tenderness to touch. In all rats, more than two joints were involved on each limb. As paw edema was most prominent on the hind-paws; only the joints in the hind-paws were assessed analytically using Tukey’s post hoc test. Joints showed a significant ($P < 0.05$) decrease in paw edema for all treated groups when compared to the untreated group (Table 1 and Figures 1(c) and 1(d)). Comparison between tocotrienol and glucosamine revealed a significantly higher ($P < 0.05$) effect of $\delta$-tocotrienol in reducing paw edema (Table 1). In the supplement-treated groups, swelling and redness over the joints reduced markedly and the rats regained their mobility. There was no recurrence of oedema in the joints and no additional joints became involved during this period (Table 1 and Figure 1).

3.3. Body Weight. Body weight of each rat was measured and recorded every five days from day 25 to 50. Although the starting weight for each group differed slightly, there was a noticeable upward trend for all groups ($P < 0.05$). The body weight of the animals ranged between 123.1 g and 138.9 g on day 35 and between 132.4 g and 156.8 g on day 50. The average body weight of all the animals rose between 10 and 12 g throughout the treatment period. The arthritis alone group had the highest ending weight. There was a significant increase in the body weight in this group after day 40 when compared with the other three groups ($P < 0.05$). The arthritic rats supplemented with $\delta$-tocotrienol showed significantly lower weight compared to the arthritis alone and control groups ($P < 0.05$) (Figure 2).
Table 1: Effect of delta-tocotrienol on percentage changes in paw edema in arthritis rats.

| Days | Left hind limb joint | Right hind limb joint |
|------|----------------------|----------------------|
|      | Arthritis           | Arthritis + tocotrienol | Arthritis + glucosamine |
|      | Arthritis           | Arthritis + glucosamine |
|      | Arthritis           | Arthritis + tocotrienol | Arthritis + glucosamine |
| Day 25 | 100 ± 2.2           | 100 ± 1.5            | 100 ± 1.5            |
| Day 30 | 98.37 ± 3.4        | 94.74 ± 2.8*         | 92.35 ± 1.2          |
| Day 35 | 95.93 ± 3.7        | 88.05 ± 3.8*         | 90.91 ± 4.1*         |
| Day 40 | 92.05 ± 4.8        | 84.35 ± 5.4*         | 88.75 ± 3.4*         |
| Day 45 | 88.42 ± 4.9        | 80.75 ± 4.3*         | 87.41 ± 2.8          |
| Day 50 | 87.24 ± 2.8        | 75.35 ± 2.7*         | 82.15 ± 3.8*         |

Data are expressed as mean ± standard error of six rats per group. * P < 0.05: arthritis versus other groups; † P < 0.05: arthritis with tocotrienol versus arthritis with glucosamine groups.

3.4. Histopathology. Histological sections were examined by light microscopy after H&E staining. All rats in the various arthritic groups showed significant changes in joint structure with varying degrees of arthritis changes. Changes observed included inflammation, cellular inflammation, joint space narrowing, synovial hyperplasia, erosion, and fibrosis. The joints of normal animals showed normal architecture with no swelling of the joint space. There was adequate gap and the articulating surfaces were lined by a healthy lining of cartilage, beneath which was the bony trabeculae. The synovium of these rats appeared healthy and there was no evidence of oedema or inflammation (Figure 3(a)). Maximum degenerative changes were observed in the arthritis alone rats, where a feature of early and late-stage inflammation such as widening of joint space during early stages of the disease was observed. Severe congestion surrounding the joint space had resulted in oedema, dilation of blood vessels, and narrowing of the joint space later on. The surface surrounding the joint space showed erosion and degeneration (Figure 3(b)). Extensive synovial hyperplasia...
was also noted with increased cellular infiltration composed primarily of inflammatory cells (lymphocytes and plasma cells). Areas of granulomatous inflammation known as pannus formed in several areas with increasing fibrosis. The tocotrienol supplemented rats showed less severe changes when compared to arthritis. Inflammation was scarce with a marked reduction in edema and congestion. Only scatters of inflammatory cells were observed, suggesting that only moderate inflammation was present. There were few focal areas of fibrosis present, indicating healing of the joint. Vascular dilation was still present accompanied by moderate synovial hyperplasia. Areas of active inflammation and healing were also noted (Figure 3(c)). The joints of the rats in the glucosamine-treated group also showed a significant reduction in swelling. Microscopically, the orientation of joint space was predominantly healthy and morphological changes were minimal. There were focal areas of mild edema and scattered inflammatory cells, amidst healthy synovial tissue. The subsynovial regions showed good vasculature and areas of fibrosis, signifying that the process of healthy healing was taking place (Figure 3(d)).

3.5. Collagen-Induced Proliferation of Splenocytes. Splenocytes from the arthritic rats showed maximum cell viability when these cells were cocultured with 5μg/mL collagen for 24, 48, and 72 hours. At 72 hours, cell viability was at its peak with 85% compared with 59% for 24 hours and 62% for 48 hours. As the concentration of collagen increased, however, it was found that the viability of cells decreased to as low as 9%. Once the optimum concentration of collagen and incubation time were determined, this data (not shown) was used to determine the proliferation of splenocytes from the control and experimental rats. Proliferation of collagen-stimulated lymphocytes was quantified using the MTT assay. The results showed that the proliferation of collagen-stimulated splenocytes was reduced in animals that were supplemented with glucosamine and δ-tocotrienol ($P < 0.05$) (Figure 4).

3.6. C-Reactive Protein (CRP). Plasma levels of C-reactive protein (CRP) were determined by using a commercial ELISA kit using the protocol recommended by the manufacturer (Millipore, USA). The arthritic group showed significantly ($P < 0.05$) elevated levels of CRP compared to the control group. There was a significant decrease in the CRP in the δ-tocotrienol and glucosamine-treated group ($P > 0.05$) when compared to the arthritis alone group (Figure 5).
being involved. No rats were severely disabled to warrant early sacrifice. Arthritis developed acutely in rats, with joint changes occurring much more rapidly than in human RA. This allowed for a more detailed observation of joint changes before and after treatment. The CIA is associated with unwanted features such as variable incidence, severity, and intergroup inconsistency [13] which were controlled by maintaining appropriate environmental conditions.

Macroscopically, all rats induced with arthritis showed similar signs and arthritis had peaked by day 25. Classical signs of CIA were observed, including symmetrical joint involvement typically involving the hind-paws, swelling, and erythema over the joints [14–16]. By the end of treatment period (day 50), treated groups showed an amelioration in signs and improved mobility of the joints. Histopathological changes correlated with macroscopic observations, including changes in paw oedema. Hallmarks of the CIA were noted and were present in varying degrees amongst the different groups. Untreated (arthritis only) rats showed maximum degenerative changes. Suppression of disease activity was seen in treated groups with the greatest changes in the δ-tocotrienol group.

Previous studies using animal models of arthritis showed that anti-inflammatory effects were attained through the inhibition of inflammatory mediators [17]. Tocotrienols have been described to inhibit these mediators, primarily TNF-α and IL-1β [17–20], which could possibly correlate with the attenuation histopathological changes found in these groups. The antioxidant qualities of tocotrienols are also a key in modulating joint injury by preventing free radical induced damage. Tocotrienols are known to possess a higher free radical quenching ability [21, 22]. Suppression of disease activity with δ-tocotrienols could be due to the fact that δ-tocotrienol is known to lower TNF-α, IL-1β, and nitric oxide levels [18, 19]. Glucosamine is a known potent antioxidant and has been used in osteoarthritis because of its ability to reduce joint damage [23]. This is consistent with our findings in which glucosamine exhibited disease attenuation property in arthritis rats.

Splenocyte proliferation was performed to determine whether treatment with δ-tocotrienol is associated with a protection against cell-mediated immunity. Proliferation of collagen-specific T-cells (CII-T) was assessed by the MTT assay. Firstly, conditions in which proliferation was maximal had to be established to determine accurate quantification of these cells. Therefore, optimisation on the concentration of collagen needed to stimulate appropriate amounts of CII-T was carried out in this study. Although the procedure for T-cell assay is well established, there seemed to be conflicting information in the literature as to the optimum concentration of collagen [24–27]. The results showed that, at a concentration of 5 μg/mL with an incubation time of 72 hours, proliferation was at its maximum. Collagen toxicity towards cells increased at concentrations greater than this. This was the case for both the normal and the arthritic rats. It has been established that T-cell infiltration is directly correlated with the severity of arthritis [26]. The assumption that increased amounts of T-cells in the synovium occur as a result of clonal expansion to specific antigens has been explored previously [28]. In the case of CIA, the autoantigen is known to be collagen type II [26]. Therefore, it is safe to assume that high levels of CII-T cells indicate an increased disease severity. It has been reported that when introduced into the dermis, collagen type II is immediately captured by antigen presenting cells (APCs). This results in the activation and expansion of CII-T cells, initiating joint damage [5]. Therefore, by quantifying levels of CII-T cells, therapeutic benefits of δ-tocotrienol and glucosamine were assessed and compared. Using the set conditions, it was found that both δ-tocotrienol and glucosamine exhibited the significant suppression of CII-T cells when compared to the untreated groups. Both of these exhibited values close to those of the normal nonarthritic rat. In comparison with each other, δ-tocotrienol exhibited a higher suppressive power than glucosamine. As such, our observation that δ-tocotrienol reduced CII-T-cell proliferation may indicate a mode of protection offered by this isomer of vitamin E against inflammatory arthritis.

It is unclear however by which exact mechanism δ-tocotrienol was able to suppress the clonal expansion of CII-T cells. We hypothesise that it could be through one of two mechanisms: (i) direct suppression of the CII-T cells or (ii) upregulation of T-regulatory (Treg) cells. Direct suppression could arise from blocking the interaction between T-cells and APCs or prevention of T-cell infiltration into the synovium [28]. Treg cells have been proposed over recent years to offer protection against RA by reducing the number of T-cells.

Biomarkers of inflammation have proven to be useful in the evaluation of disease progression and response to therapeutic intervention in a number of systemic inflammatory disorders, including RA. One such marker is C-reactive protein (CRP). An acute phase protein, CRP, is produced in the liver under conditions of systemic inflammation. It is reported to be a very useful marker of inflammation as its half life does not alter in health and disease states and it directly correlates with the intensity of pathological processes [12]. In clinically active human rheumatoid arthritis, levels of CRP are found to be increased [30]. This is translated across to animal models of rheumatoid arthritis where a similar process is observed [12]. One study demonstrated that high CRP levels are associated with incidence of total joint replacement in patients with arthritis and lower levels of CRP correspond to sustained suppression of the disease [12]. CRP levels have also been shown to be good markers for inflammation, bone degradation, and clinical well-being of patients with rheumatoid arthritis [12]. Studies have also shown that plasma CRP does not tend to rise substantially in response to inflammation in rats [31]. Plasma CRP level decreased significantly with δ-tocotrienol and glucosamine
treatment in this study. The δ-tocotrienol and glucosamine groups still had significantly lower levels of CRP by the end of the experimental cycle compared to arthritis alone group [12, 19, 30]. Production in CRP is activated by synovial macrophages and fibroblasts mostly via a number of inflammatory cytokines including TNF-α, IL-1, and especially IL-6 [32]. These cytokines are similarly produced in abundance in RA; thus it can be said that lowered levels of CRP with tocotrienol treatment signify decreased cytokine production and consequently decreased disease activity.

5. Conclusions

In conclusion, this study has demonstrated that oral supplementation of δ-tocotrienol potently attenuates the development of progressive joint destruction in rats with CIA. This effect is due, in part, to their ability to inhibit T-cell proliferation, reverse histopathological changes, and inhibit production of proinflammatory cytokines. The properties exhibited by δ-tocotrienol showed promising outcomes against collagen-induced arthritis in this study. Therefore, there is clear evidence to suggest the potential benefits for this tocotrienol to be used as therapeutic agent in rheumatoid arthritis. Furthermore, insight into the possible mechanisms of this drug and disease should be uncovered to unleash a whole new realm of therapeutic possibilities.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

All authors contributed equally to this research work.

References

[1] B. H. Toh, S. Sengupta, A. H. Ang, J. C. White, and K. S. Lau, “Pattern of rheumatoid arthritis in West Malaysia,” *Annals of the Rheumatic Diseases*, vol. 32, no. 2, pp. 151–156, 1973.

[2] C. A. Smith and F. C. Arnett, “Epidemiologic aspects of rheumatoid arthritis. Current immunogenetic approach,” *Clinical Orthopaedics and Related Research*, vol. 265, pp. 23–35, 1991.

[3] S. Chaiammuay and S. L. Bridges Jr., “The role of B cells and autoantibodies in rheumatoid arthritis,” *Pathophysiology*, vol. 12, no. 3, pp. 203–216, 2005.

[4] E. Romas, M. T. Gillespie, and T. J. Martin, “Involvement of receptor activator of NFκB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis,” *Bone*, vol. 30, no. 2, pp. 340–346, 2002.

[5] E. K. Kalra, “Nutraceutical—definition and introduction,” *AAPS PharmSciTech*, vol. 5, no. 3, article E25, 2003.

[6] G. B. Lockwood, “The quality of commercially available nutraceutical supplements and food sources,” *The Journal of Pharmacy and Pharmacology*, vol. 63, no. 1, pp. 3–10, 2011.

[7] K. Sundram, R. Sambanthamarthi, and Y. A. Tan, “Palm fruit chemistry and nutrition,” *Asia Pacific Journal of Clinical Nutrition*, vol. 12, no. 3, pp. 355–362, 2003.

[8] A. Kamal-Eldin and L. A. Appelqvist, “The chemistry and antioxidant properties of tocopherols and tocotrienols,” *Lipids*, vol. 31, no. 7, pp. 671–701, 1996.

[9] P. Ramdas, M. Rajihuzzaman, S. D. Veerasenan, K. R. Selvaduray, K. Nesaretnam, and A. K. Radhakrishnan, “Tocotrienol-treated MCF-7 human breast cancer cells show down-regulation of API5 and up-regulation of MIG6 genes,” *Cancer Genomics Proteomics*, vol. 8, no. 1, pp. 19–31, 2011.

[10] N. A. Kelsey, H. M. Wilkins, and D. A. Linseman, “Nutraceutical antioxidants as novel neuroprotective agents,” *Molecules*, vol. 15, no. 11, pp. 7792–7814, 2010.

[11] M. P. Vierboom, E. Breedveld, I. Kondova, and B. A. ’t Hart, “Collagen-induced arthritis in common marmosets: a new non-human primate model for chronic arthritis,” *Arthritis Research & Therapy*, vol. 12, no. 5, article R200, 2010.

[12] J. P. Portanova, Y. Zhang, G. D. Anderson et al., “Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo,” *The Journal of Experimental Medicine*, vol. 184, no. 3, pp. 883–891, 1996.

[13] C. Steffen and R. Timpl, “Antigenicity of collagen and its application in the serological investigation of rheumatoid arthritis sera,” *International Archives of Allergy and Applied Immunology*, vol. 22, pp. 333–349, 1963.

[14] D. L. Asquith, A. M. Miller, I. B. Mclnnes, and F. Y. Liew, “Animal models of rheumatoid arthritis,” *European Journal of Immunology*, vol. 39, no. 8, pp. 2040–2044, 2009.

[15] D. D. Brand, A. H. Kang, and E. F. Rosloniec, “Immunopathogenesis of collagen arthritis,” *Springer Seminars in Immunopathology*, vol. 25, no. 1, pp. 3–18, 2003.

[16] M. Ueno, K. Imaizumi, T. Sugita, I. Takata, and M. Takeshita, “Effect of a novel anti-rheumatic drug, TA-383, on type II collagen-induced arthritis,” *International Journal of Immunopharmacology*, vol. 17, no. 7, pp. 597–603, 1995.

[17] K. S. Ahn, G. Sethi, K. Krishnan, and B. B. Aggarwal, “Gamma-tocotrienol inhibits nuclear factor-kappaB signaling pathway through inhibition of receptor-interacting protein and TAK1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis,” *The Journal of Biological Chemistry*, vol. 282, no. 1, pp. 809–820, 2007.

[18] A. A. Qureshi, J. C. Reis, C. J. Papasian, D. C. Morrison, and N. Qureshi, “Tocotrienols inhibit lipopolysaccharide-induced pro-inflammatory cytokines in macrophages of female mice,” *Lipids in Health and Disease*, vol. 9, no. 1, p. 143, 2010.

[19] A. A. Qureshi, J. C. Reis, N. Qureshi, C. J. Papasian, D. C. Morrison, and D. M. Schaefer, “δ-tocotrienol and quercetin reduce serum levels of nitric oxide and lipid parameters in female chickens,” *Lipids in Health and Disease*, vol. 10, article 39, 2011.

[20] C. W. Chen and H. H. Cheng, “A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes,” *The Journal of Nutrition*, vol. 136, no. 6, pp. 1472–1476, 2006.

[21] P. Palozza, S. Verdecchia, L. Avanzi et al., “Comparative antioxidant activity of tocotrienols and the novel chromanol-polyisoprenyl molecule FeAox-6 in isolated membranes and intact cells,” *Molecular and Cellular Biochemistry*, vol. 287, no. 1-2, pp. 21–32, 2006.

[22] M. L. Yam, S. R. Abdul Hafid, H. M. Cheng, and K. Nesaretnam, “Tocotrienols suppress proinflammatory markers and cyclooxygenase-2 expression in RAW264.7 macrophages,” *Lipids*, vol. 44, no. 9, pp. 787–797, 2009.
[23] H. Akama and S. Saito, “Glucosamine and chondroitin for osteoarthritis,” *Arthritis & Rheumatology*, vol. 45, no. 1, p. 107, 2001.

[24] K. Kannan, R. A. Ortmann, and D. Kimpel, “Animal models of rheumatoid arthritis and their relevance to human disease,” *Pathophysiology*, vol. 12, no. 3, pp. 167–181, 2005.

[25] S. Nakae, A. Nambu, K. Sudo, and Y. Iwakura, “Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice,” *Journal of Immunology*, vol. 171, no. 11, pp. 6173–6177, 2003.

[26] T. Tomita, Y. Kakiuchi, and P. S. Tsao, “THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis,” *Arthritis Research & Therapy*, vol. 8, no. 1, article R7, 2006.

[27] T. Ostberg, H. Wahamaa, K. Palmblad et al., “Oxaliplatin retains HMGB1 intranuclearly and ameliorates collagen type II-induced arthritis,” *Arthritis Research & Therapy*, vol. 10, no. 1, pp. R1, 2008.

[28] U. Andersson and K. J. Tracey, ”HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis,” *Rheumatic Diseases Clinics of North America*, vol. 30, no. 3, pp. 627–637, 2004.

[29] A. Skapenko, J. Leipe, P. E. Lipsky, and H. Schulze-Koops, “The role of the T cell in autoimmune inflammation,” *Arthritis Research & Therapy*, vol. 7, supplement 2, pp. S4–S14, 2005.

[30] C. D. Poole, P. Conway, A. Reynolds, and C. J. Currie, ”The association between C-reactive protein and the likelihood of progression to joint replacement in people with rheumatoid arthritis: a retrospective observational study,” *BMC Musculoskeletal Disorders*, vol. 9, p. 146, 2008.

[31] E. Larsson, H. Erlandsson Harris, J. C. Lorentzen, A. Larsson, B. Mansson, and L. Klareskog, ”Serum concentrations of cartilage oligomeric matrix protein, fibrinogen and hyaluronan distinguish inflammation and cartilage destruction in experimental arthritis in rats,” *Rheumatology*, vol. 41, no. 9, pp. 996–1000, 2002.

[32] D. J. Brull, N. Serrano, F. Zito et al., ”Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease,” *Atherosclerosis, Thrombosis, and Vascular Biology*, vol. 23, no. 11, pp. 2063–2069, 2003.
